|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/23/22 Nunzia Pharmaceutical Co. 10-Q 3/31/22 30:1.3M GlobalOne Filings Inc/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 225K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 15K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 15K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 12K
10: R1 Cover HTML 59K
11: R2 Consolidated Balance Sheets (Unaudited) HTML 74K
12: R3 Consolidated Balance Sheets (Unaudited) HTML 22K
(Parenthetical)
13: R4 Consolidated Statements of Operations (Unaudited) HTML 90K
14: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 53K
15: R6 Basis of Presentation, Organization, Going Concern HTML 21K
and Recent Accounting Pronouncements
16: R7 Summary of Significant Accounting Policies HTML 30K
17: R8 Preferred and Common Stock HTML 22K
18: R9 Commitments and Contingencies HTML 18K
19: R10 Transactions with Related Persons HTML 18K
20: R11 Subsequent Events HTML 14K
21: R12 Summary of Significant Accounting Policies HTML 57K
(Policies)
22: R13 Basis of Presentation, Organization, Going Concern HTML 15K
and Recent Accounting Pronouncements (Details
Narrative)
23: R14 Summary of Significant Accounting Policies HTML 14K
(Details Narrative)
24: R15 Preferred and Common Stock (Details Narrative) HTML 32K
25: R16 Transactions with Related Persons (Details HTML 26K
Narrative)
28: XML IDEA XML File -- Filing Summary XML 44K
26: XML XBRL Instance -- nunzia_i10q-033122_htm XML 203K
27: EXCEL IDEA Workbook of Financial Reports XLSX 30K
6: EX-101.CAL XBRL Calculations -- nunz-20220331_cal XML 51K
7: EX-101.DEF XBRL Definitions -- nunz-20220331_def XML 112K
8: EX-101.LAB XBRL Labels -- nunz-20220331_lab XML 274K
9: EX-101.PRE XBRL Presentations -- nunz-20220331_pre XML 213K
5: EX-101.SCH XBRL Schema -- nunz-20220331 XSD 39K
29: JSON XBRL Instance as JSON Data -- MetaLinks 126± 162K
30: ZIP XBRL Zipped Folder -- 0001683168-22-003887-xbrl Zip 54K
EXHIBIT 31.2
CERTIFICATION PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A)
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED
I, Michael Mitsunaga, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Nunzia Pharmaceutical Company; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; | |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; | |
| (c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and | |
| (d) | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting. |
| 5. | I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and | |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
| Date: May 23, 2022 | By: /s/ Michael Mitsunaga | |
| Name: Michael Mitsunaga | ||
| Title: President, Chief Financial Officer | ||
| (Principal Financial Officer and Principal Accounting Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/23/22 | |||
| For Period end: | 3/31/22 | NT 10-K, NT 10-Q | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/04/21 Nunzia Pharmaceutical Co. 8-K©:1 8/03/21 1:27K 1562884 5/07/21 Nunzia Pharmaceutical Co. 8-K©:1 4/12/21 1:337K 1562884 |